Novavax (NASDAQ: NVAX) share are trading lower after the FDA suggested that the company’s Covid-19 vaccine could cause heart inflammation. The stock is currently down 26% down at the time of posting.
Novavax (NASDAQ: NVAX) share are trading lower after the FDA suggested that the company’s Covid-19 vaccine could cause heart inflammation. The stock is currently down 26% down at the time of posting.